ライフサイエンスコーパス: ANCA-positive

1 At the time of KTX, 29 patients were ANCA-positive.

2 nical and prognostic differences between PR3-ANCA-positive and MPO-ANCA-positive patients, supports a

3 ore frequently relapsing, PR3 (proteinase 3)-ANCA positive, and had lower serum creatinine but were m

4 Speckled ANCA (sANCA) subjects were ANCA positive by ELISA with a speckling over the entire

5 f HNE ANCA-positive CIMDL sera were also PR3 ANCA-positive by at least 1 assay.

6 ]), and antineutrophil cytoplasmic antibody (ANCA)-positive cases were compared with control groups.

7 Fifty-seven percent of HNE ANCA-positive CIMDL sera were also PR3 ANCA-positive by

8 that the efficacy of mepolizumab for CRS in ANCA-positive EGPA varies among patients.

9 We report two cases of MPO-ANCA-positive EGPA with CRS that exhibited differing res

10 e subset of 27 patients with myeloperoxidase-ANCA-positive GPA, 8 of 10 rituximab recipients and 8 of

11 e 3-antineutrophil cytoplasmic antibody (PR3-ANCA)-positive IgG preparations or myeloperoxidase-ANCA

12 gG preparations or myeloperoxidase-ANCA (MPO-ANCA)-positive IgG preparations to activate neutrophils

13 The present study examined the effects of ANCA-positive IgG (ANCA IgG), derived from patients with

14 were perfused in the presence or absence of ANCA-positive IgG over endothelial cells that had been a

15 ositive IgG preparations 0.735 +/- 0.10, PR3-ANCA-positive IgG preparations 0.33 +/- 0.098; P < 0.01)

16 /- 0.35 nmoles; P < 0.001), Ca2+ fluxes (MPO-ANCA-positive IgG preparations 0.735 +/- 0.10, PR3-ANCA-

17 ive IgG preparations 251.98 +/- 26.7 ng, PR3-ANCA-positive IgG preparations 145.19 +/- 19.4 ng; P < 0

18 0.098; P < 0.01), and MPO degranulation (MPO-ANCA-positive IgG preparations 251.98 +/- 26.7 ng, PR3-A

19 ons 9.13 +/- 0.39 nmoles [mean +/- SEM], PR3-ANCA-positive IgG preparations 6.32 +/- 0.35 nmoles; P <

20 greater generation of superoxide anions (MPO-ANCA-positive IgG preparations 9.13 +/- 0.39 nmoles [mea

21 G4 were the predominant isotypes in both MPO-ANCA-positive IgG preparations and PR3-ANCA.

22 In vitro MPO-ANCA-positive IgG preparations are more activating than

23 Activation of PMN by MPO-ANCA-positive IgG preparations compared with PR3-ANCA-po

24 icantly more IgG1 than did PR3-ANCA, and PR3-ANCA-positive IgG preparations contained significantly m

25 -positive IgG preparations compared with PR3-ANCA-positive IgG preparations resulted in greater gener

26 The increased activation seen with MPO-ANCA-positive IgG preparations was not due to increased

27 cell surface or greater IgG3 present in MPO-ANCA-positive IgG preparations.

28 gG preparations are more activating than PR3-ANCA-positive IgG preparations.

29 at incorporate ANCA specificity, such as PR3 ANCA-positive MPA and MPO ANCA-positive MPA, provide a m

30 icity, such as PR3 ANCA-positive MPA and MPO ANCA-positive MPA, provide a more useful tool than the c

31 cificity was predictive of relapse, with PR3 ANCA-positive patients almost twice as likely to relapse

32 A retrospective cohort study of MPO- or PR3-ANCA-positive patients with AAV (MPA and GPA) and severe

33 Clinical profiles of the ANCA-positive patients with CD were compared with those

34 Interestingly, MPO-ANCA-positive patients with either MPA or EGPA have over

35 Nine centers enrolled 197 ANCA-positive patients with either Wegener's granulomato

36 One hundred seven ANCA-positive patients with necrotizing and crescentic g

37 Sera from 61 PR3 ANCA-positive patients with WG or MPA were assayed by ca

38 ifferences between PR3-ANCA-positive and MPO-ANCA-positive patients, supports an ANCA-based re-classi

39 , in contrast to anti-LAMP-2 antibodies from ANCA-positive patients, these antibodies from ANCA-negat

40 and FACS analysis demonstrate reactivity of ANCA-positive sera and antimyeloperoxidase antibodies wi

41 IgG from NE ANCA-positive sera of patients with CIMDL inhibited the

42 Sixty percent of ANCA-positive sera showed a perinuclear reaction pattern

43 induce antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis (APV) are largely unknown.

44 ed with antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis.

45 e demonstrates that patients with idiopathic ANCA-positive vasculitis may quickly develop a superimpo

46 ickly develop a superimposed drug-associated ANCA-positive vasculitis.

47 azine or propylthiouracil is associated with ANCA-positive vasculitis.

48 which can be stratified on ANCA-status (MPO ANCA-positive versus ANCA-negative); these subsets diffe